Dr. Nakazawa is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2020 - 2023
Perelman School of Medicine at the University of PennsylvaniaClass of 2017
University of PennsylvaniaPhD, Cell and Molecular Biology, 2011 - 2015
Certifications & Licensure
TX State Medical License 2021 - 2026
CA State Medical License 2018 - 2020- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Conquer Cancer Young Investigator Award ASCO, 2022
Publications & Presentations
PubMed
- 1 citationsLoss of the DNA Repair Gene RNase H2 Identifies a Unique Subset of DDR-Deficient Leiomyosarcomas.Michael S Nakazawa, Ian M Silverman, Victoria Rimkunas, Artur Veloso, Dominik Glodzik
Molecular Cancer Therapeutics. 2024-07-02 - 1 citationsHigh-Grade Pleomorphic Sarcomas Treated with Immune Checkpoint Blockade: The MD Anderson Cancer Center Experience.Lewis F Nasr, Marianne Zoghbi, Rossana Lazcano, Michael Nakazawa, Andrew J Bishop
Cancers. 2024-05-01 - 1 citationsUtility of Clinical Next Generation Sequencing Tests in KIT/PDGFRA/SDH Wild-Type Gastrointestinal Stromal Tumors.Ryan A Denu, Cissimol P Joseph, Elizabeth S Urquiola, Precious S Byrd, Richard K Yang
Cancers. 2024-04-27
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
